These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15354740)

  • 1. Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett's esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett's esophagus.
    Gulmann C; Shaqaqi OA; Grace A; Leader M; Patchett S; Butler D; Kay E
    Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):142-7. PubMed ID: 15354740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach.
    Ormsby AH; Goldblum JR; Rice TW; Richter JE; Falk GW; Vaezi MF; Gramlich TL
    Hum Pathol; 1999 Mar; 30(3):288-94. PubMed ID: 10088547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia.
    Mohammed IA; Streutker CJ; Riddell RH
    Mod Pathol; 2002 Jun; 15(6):611-6. PubMed ID: 12065774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinction between short-segment Barrett's esophageal and cardiac intestinal metaplasia.
    Liu GS; Gong J; Cheng P; Zhang J; Chang Y; Qiang L
    World J Gastroenterol; 2005 Oct; 11(40):6360-5. PubMed ID: 16419166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction.
    Jovanovic I; Tzardi M; Mouzas IA; Micev M; Pesko P; Milosavljevic T; Zois M; Sganzos M; Delides G; Kanavaros P
    Histol Histopathol; 2002 Apr; 17(2):445-54. PubMed ID: 11962749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus.
    DeMeester SR; Wickramasinghe KS; Lord RV; Friedman A; Balaji NS; Chandrasoma PT; Hagen JA; Peters JH; DeMeester TR
    Am J Gastroenterol; 2002 Oct; 97(10):2514-23. PubMed ID: 12385432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction.
    Shen B; Ormsby AH; Shen C; Dumot JA; Shao YW; Bevins CL; Gramlich TL
    Cancer; 2002 Feb; 94(3):820-31. PubMed ID: 11857318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI.
    Glickman JN; Wang H; Das KM; Goyal RK; Spechler SJ; Antonioli D; Odze RD
    Am J Surg Pathol; 2001 Jan; 25(1):87-94. PubMed ID: 11145256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.
    Couvelard A; Cauvin JM; Goldfain D; Rotenberg A; Robaszkiewicz M; Fléjou JF;
    Gut; 2001 Dec; 49(6):761-6. PubMed ID: 11709508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients.
    Schilling D; Spiethoff A; Rosenbaum A; Hartmann D; Eickhoff A; Jakobs R; Weickert U; Rebe M; Bohrer MH; Riemann JF
    Pathol Res Pract; 2005; 200(11-12):801-5. PubMed ID: 15792123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and immunohistochemistry.
    Sarbia M; Donner A; Franke C; Gabbert HE
    Hum Pathol; 2004 Mar; 35(3):371-6. PubMed ID: 15017595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus.
    Ormsby AH; Vaezi MF; Richter JE; Goldblum JR; Rice TW; Falk GW; Gramlich TL
    Gastroenterology; 2000 Sep; 119(3):683-90. PubMed ID: 10982762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach.
    Flucke U; Steinborn E; Dries V; Mönig SP; Schneider PM; Thiele J; Hölscher AH; Dienes HP; Baldus SE
    Histopathology; 2003 Aug; 43(2):127-34. PubMed ID: 12877727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic differences between esophageal and gastric intestinal metaplasia.
    Piazuelo MB; Haque S; Delgado A; Du JX; Rodriguez F; Correa P
    Mod Pathol; 2004 Jan; 17(1):62-74. PubMed ID: 14631367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucin core peptide expression can help differentiate Barrett's esophagus from intestinal metaplasia of the stomach.
    Glickman JN; Shahsafaei A; Odze RD
    Am J Surg Pathol; 2003 Oct; 27(10):1357-65. PubMed ID: 14508397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is cytokeratin immunoreactivity useful in the diagnosis of short-segment Barrett's oesophagus in Korea?
    Yim HJ; Lee SW; Choung RS; Kim YS; Kim JY; Lee HS; Song CW; Choi JH; Bak YT; Ryu HS; Hyun JH; Kim DS; Kim CH
    Eur J Gastroenterol Hepatol; 2005 Jun; 17(6):611-6. PubMed ID: 15879722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens.
    El-Zimaity HM; Graham DY
    Am J Gastroenterol; 2001 May; 96(5):1378-82. PubMed ID: 11374671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profile and cellular localizations of mucin proteins, CK7, and cytoplasmic p27 in Barrett's esophagus and esophageal adenocarcinoma.
    Ozcan HEA; Anuk T; Ozden O
    Adv Med Sci; 2018 Sep; 63(2):296-300. PubMed ID: 29803118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of cytokeratin immunoreactivity pattern for distinction of Barrett's esophagus from intestinal metaplasia of the stomach.
    Iwata T; Kurita N; Nishioka M; Hidenori M; Wakatsuki S; Sano T; Shimada M
    Hepatogastroenterology; 2007 Sep; 54(78):1710-2. PubMed ID: 18019700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etiology of intestinal metaplasia at the gastroesophageal junction.
    Balaji NS; DeMeester SR; Wickramasinghe KS; Hagen JA; Peters JH; DeMeester TR
    Surg Endosc; 2003 Jan; 17(1):43-8. PubMed ID: 12364989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.